Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Has Two Patents For Gene Expression Tool


NEW HAVEN, Conn.--CuraGen said it has been granted a second US patent covering its open architecture technology for discovering genes, measuring gene expression, and enabling pharmacogenomics research. Specifically, the company said the new patent covers the apparatus and computer systems utilized in its GeneCalling system, which was discussed in a peer-reviewed paper published in the August, 1999, issue of Nature Biotechnology. GeneCalling is a high-throughput method for analyzing differences in gene expression and gene sequence and comparing results to public and proprietary sequence databases.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.